Multiple Liver Metastases from Carcinoma of the Thymus Treated with Yttrium-90 Radioembolization (Glass Microspheres): Clinical Dosimetry

Ferreira P, Parafita R, Canudo A, Oliveira C, Rosa L, Girão P and Costa DC

Champalimaud Centre for the Unknown, Champalimaud Foundation, Portugal
Instituto Superior Técnico - Universidade de Lisboa, Lisboa, Portugal
Mercurius Health, Portugal

^*Correspondance to: Paulo Ferreira 

 PDF  Full Text Research Article | Open Access

Abstract:

Liver radioembolization with Yttrium-90 microspheres has been recognized as an emerging treatment strategy for patients with primary hepatic malignancies and metastatic liver disease. Furthermore, a shift toward the curative setting is desirable although Yttrium-90 radioembolization is primarily performed in the palliative setting. Unfortunately, there is little information on complex patient dosimetry based on real absorbed dose distribution to the normal liver, tumor and extrahepatic tissues, from patients submitted to radioembolization. We herein describe the case report of our first patient (multiple diffuse liver metastases failing to respond to sunitinib) submitted to radioembolization with Yttrium-90 glass microspheres at the Champalimaud Centre for the Unknown (CCU), Champalimaud Foundation (FC), focusing on complex patient clinical dosimetry based on absorbed dose calculation Stratos algorithm software. This new research approach enabled to calculate the tumor liver dose to be 118 Gy very close to the pre-therapy prescribed 120 Gy. The maximum recommended normal liver dose was not reached. It was equal to 12 Gy.

Keywords:

Yttrium-90; 99mTc-MAA; Radioembolization; Dosimetry; Treatment planning; Dose-Volume Histogram; SPECT; PET; PET/CT

Cite the Article:

Ferreira P, Parafita R, Canudo A, Oliveira C, Rosa L, Girão P, et al. Multiple Liver Metastases from Carcinoma of the Thymus Treated with Yttrium-90 Radioembolization (Glass Microspheres): Clinical Dosimetry. Clin Oncol. 2016; 1: 1024.